Sanofi
Sanofi provides therapeutic solutions worldwide. The last earnings update was 48 days ago. More info.
Add to Portfolio Compare Print
SAN Share Price and Events
7 Day Returns
1 Year Returns
SAN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Sanofi (SAN) | 1% | -6% | 0.5% | 11% | -3.4% | -5.6% |
| FR Pharmaceuticals | 1.5% | -3.7% | 2.3% | 10.7% | 2.1% | 2.6% |
| FR Market | 0.5% | 6.3% | 14.4% | 4.1% | 29.1% | 33.1% |
1 Year Return vs Industry and Market
- SAN outperformed the Market in France which returned 4.1% over the past year.
Value
Is Sanofi undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Sanofi
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Sanofi.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 19 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 6.8% |
| Perpetual Growth Rate | 10-Year FR Government Bond Rate | 0.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year FR Govt Bond Rate | 0.7% |
| Equity Risk Premium | S&P Global | 6.7% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.73 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 33%) (26.86%)) |
0.909 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.91 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (0.909 * 6.65%) |
6.78% |
Discounted Cash Flow Calculation for ENXTPA:SAN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Sanofi is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (EUR, Millions) | Source |
Present Value Discounted (@ 6.78%) |
|
|---|---|---|---|
| 2019 | 6,904.53 | Analyst x9 | 6,466.37 |
| 2020 | 6,990.94 | Analyst x8 | 6,131.81 |
| 2021 | 7,765.16 | Analyst x6 | 6,378.67 |
| 2022 | 8,987.00 | Analyst x2 | 6,913.88 |
| 2023 | 8,873.50 | Analyst x2 | 6,393.35 |
| 2024 | 8,814.02 | Est @ -0.67% | 5,947.50 |
| 2025 | 8,792.04 | Est @ -0.25% | 5,556.19 |
| 2026 | 8,796.02 | Est @ 0.05% | 5,205.96 |
| 2027 | 8,818.16 | Est @ 0.25% | 4,887.86 |
| 2028 | 8,853.08 | Est @ 0.4% | 4,595.81 |
| Present value of next 10 years cash flows | €58,477.40 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= €8,853.08 × (1 + 0.73%) ÷ (6.78% – 0.73%) |
€147,577.71 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= €147,577.71 ÷ (1 + 6.78%)10 |
€76,610.49 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= €58,477.40 + €76,610.49 |
€135,087.89 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €135,087.89 / 1,245.97 |
€108.42 |
| Calculation | Result | |
|---|---|---|
| Value per share (EUR) | From above. | €108.42 |
| Current discount | Discount to share price of
€73.62
= -1 x (€73.62 - €108.42) / €108.42 |
32.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Sanofi's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Sanofi's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Sanofi's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Sanofi's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in EUR | €3.46 |
| ENXTPA:SAN Share Price ** | ENXTPA (2019-04-25) in EUR | €73.62 |
| France Pharmaceuticals Industry PE Ratio | Median Figure of 6 Publicly-Listed Pharmaceuticals Companies | 23.69x |
| France Market PE Ratio | Median Figure of 416 Publicly-Listed Companies | 16.23x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Sanofi.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTPA:SAN Share Price ÷ EPS (both in EUR) = 73.62 ÷ 3.46 |
21.26x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sanofi is good value based on earnings compared to the FR Pharmaceuticals industry average.
- Sanofi is overvalued based on earnings compared to the France market.
Price based on expected Growth
Does
Sanofi's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 21.26x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts |
12.2%per year |
| France Pharmaceuticals Industry PEG Ratio | Median Figure of 6 Publicly-Listed Pharmaceuticals Companies | 2.14x |
| France Market PEG Ratio | Median Figure of 273 Publicly-Listed Companies | 1.54x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 21.26x ÷ 12.2% |
1.75x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sanofi is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Sanofi's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in EUR | €47.27 |
| ENXTPA:SAN Share Price * | ENXTPA (2019-04-25) in EUR | €73.62 |
| France Pharmaceuticals Industry PB Ratio | Median Figure of 8 Publicly-Listed Pharmaceuticals Companies | 1.9x |
| France Market PB Ratio | Median Figure of 617 Publicly-Listed Companies | 1.47x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTPA:SAN Share Price ÷ Book Value per Share (both in EUR) = 73.62 ÷ 47.27 |
1.56x |
* Primary Listing of Sanofi.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sanofi is good value based on assets compared to the FR Pharmaceuticals industry average.
Value checks
We assess Sanofi's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Sanofi has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Sanofi expected to perform in the next 1 to 3 years based on estimates from 19 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Sanofi's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
- Sanofi's earnings growth is positive but not above the France market average.
- Sanofi's revenue growth is positive but not above the France market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ENXTPA:SAN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts | 12.2% |
| ENXTPA:SAN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts | 3.2% |
| France Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 12.7% |
| France Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 3.7% |
| France Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| France Market Revenue Growth Rate | Market Cap Weighted Average | 4.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 41,004 | 10,067 | 7,794 | 7 |
| 2022-12-31 | 40,410 | 9,869 | 7,658 | 7 |
| 2021-12-31 | 39,200 | 9,620 | 6,755 | 10 |
| 2020-12-31 | 37,419 | 8,865 | 5,842 | 16 |
| 2019-12-31 | 35,883 | 8,366 | 5,056 | 15 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 35,677 | 5,547 | 4,319 |
| 2018-09-30 | 35,316 | 4,041 | |
| 2018-06-30 | 34,968 | 6,596 | 3,261 |
| 2018-03-31 | 35,428 | 3,539 | |
| 2017-12-31 | 36,221 | 7,379 | 3,773 |
| 2017-09-30 | 36,400 | 4,593 | |
| 2017-06-30 | 36,315 | 8,133 | 4,744 |
| 2017-03-31 | 35,677 | 4,682 | |
| 2016-12-31 | 34,696 | 7,838 | 4,395 |
| 2016-09-30 | 34,349 | 4,195 | |
| 2016-06-30 | 34,115 | 8,122 | 4,154 |
| 2016-03-31 | 34,569 | 4,440 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
All data from Sanofi Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 6.31 | 6.88 | 5.55 | 3.00 |
| 2022-12-31 | 6.29 | 6.60 | 5.89 | 3.00 |
| 2021-12-31 | 5.34 | 5.79 | 4.85 | 6.00 |
| 2020-12-31 | 4.66 | 5.16 | 3.88 | 9.00 |
| 2019-12-31 | 4.05 | 4.57 | 3.21 | 9.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-12-31 | 3.46 |
| 2018-09-30 | 3.24 |
| 2018-06-30 | 2.61 |
| 2018-03-31 | 2.82 |
| 2017-12-31 | 3.00 |
| 2017-09-30 | 3.63 |
| 2017-06-30 | 3.73 |
| 2017-03-31 | 3.66 |
| 2016-12-31 | 3.42 |
| 2016-09-30 | 3.25 |
| 2016-06-30 | 3.20 |
| 2016-03-31 | 3.41 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Sanofi's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Sanofi has a total score of 1/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Sanofi performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Sanofi's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Sanofi's 1-year earnings growth exceeds its 5-year average (14.5% vs -0.7%)
- Sanofi's earnings growth has exceeded the Europe Pharmaceuticals industry average in the past year (14.5% vs 13.5%).
Earnings and Revenue History
All data from Sanofi Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 35,677.00 | 4,319.00 | 9,934.00 | 5,894.00 |
| 2018-09-30 | 35,316.00 | 4,041.00 | 9,906.00 | 5,680.00 |
| 2018-06-30 | 34,968.00 | 3,261.00 | 9,904.00 | 5,560.00 |
| 2018-03-31 | 35,428.00 | 3,539.00 | 9,980.00 | 5,443.00 |
| 2017-12-31 | 36,221.00 | 3,773.00 | 10,164.00 | 5,472.00 |
| 2017-09-30 | 36,400.00 | 4,593.00 | 10,077.00 | 5,445.00 |
| 2017-06-30 | 36,315.00 | 4,744.00 | 10,034.00 | 5,325.00 |
| 2017-03-31 | 35,677.00 | 4,682.00 | 9,866.00 | 5,246.00 |
| 2016-12-31 | 34,696.00 | 4,395.00 | 9,592.00 | 5,172.00 |
| 2016-09-30 | 34,349.00 | 4,195.00 | 9,479.00 | 5,099.00 |
| 2016-06-30 | 34,115.00 | 4,154.00 | 9,452.00 | 5,191.00 |
| 2016-03-31 | 34,569.00 | 4,440.00 | 9,458.00 | 5,158.00 |
| 2015-12-31 | 34,861.00 | 4,411.00 | 9,496.00 | 5,082.00 |
| 2015-09-30 | 37,201.00 | 5,292.00 | 10,154.00 | 5,195.00 |
| 2015-06-30 | 32,910.00 | 4,628.00 | 8,873.00 | 4,745.00 |
| 2015-03-31 | 35,074.00 | 4,329.00 | 9,609.00 | 4,884.00 |
| 2014-12-31 | 31,999.00 | 4,273.00 | 8,565.00 | 4,667.00 |
| 2014-09-30 | 33,484.00 | 4,112.00 | 8,945.00 | 4,719.00 |
| 2014-06-30 | 33,134.00 | 4,140.00 | 8,640.00 | 4,755.00 |
| 2014-03-31 | 33,074.00 | 3,812.00 | 8,699.00 | 4,752.00 |
| 2013-12-31 | 31,291.00 | 3,639.00 | 8,107.00 | 4,605.00 |
| 2013-09-30 | 33,424.00 | 3,127.00 | 8,824.00 | 4,895.00 |
| 2013-06-30 | 34,146.00 | 3,364.00 | 9,153.00 | 4,840.00 |
| 2013-03-31 | 35,177.00 | 4,162.00 | 8,960.00 | 4,905.00 |
| 2012-12-31 | 35,957.00 | 4,888.00 | 9,129.00 | 4,905.00 |
| 2012-09-30 | 36,217.00 | 5,996.00 | 8,814.00 | 4,857.00 |
| 2012-06-30 | 36,149.00 | 6,431.00 | 8,834.00 | 4,921.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Sanofi has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Sanofi used its assets less efficiently than the FR Pharmaceuticals industry average last year based on Return on Assets.
- Sanofi's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Sanofi's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Sanofi has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Sanofi's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Sanofi's finances.
The net worth of a company is the difference between its assets and liabilities.
- Sanofi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Sanofi's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Sanofi Company Filings, last reported 3 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 59,035.00 | 24,640.00 | 7,154.00 |
| 2018-09-30 | 56,361.00 | 28,941.00 | 7,493.00 |
| 2018-06-30 | 56,361.00 | 28,941.00 | 7,493.00 |
| 2018-03-31 | 58,253.00 | 27,002.00 | 12,799.00 |
| 2017-12-31 | 58,239.00 | 15,601.00 | 10,392.00 |
| 2017-09-30 | 57,792.00 | 18,427.00 | 10,877.00 |
| 2017-06-30 | 57,792.00 | 18,427.00 | 10,877.00 |
| 2017-03-31 | 57,724.00 | 18,581.00 | 10,307.00 |
| 2016-12-31 | 57,722.00 | 18,581.00 | 10,307.00 |
| 2016-09-30 | 54,347.00 | 17,277.00 | 6,206.00 |
| 2016-06-30 | 54,347.00 | 17,277.00 | 6,206.00 |
| 2016-03-31 | 58,210.00 | 16,558.00 | 9,200.00 |
| 2015-12-31 | 58,210.00 | 16,558.00 | 9,200.00 |
| 2015-09-30 | 56,774.00 | 14,732.00 | 4,927.00 |
| 2015-06-30 | 56,774.00 | 14,732.00 | 4,927.00 |
| 2015-03-31 | 56,268.00 | 14,816.00 | 7,448.00 |
| 2014-12-31 | 56,268.00 | 14,816.00 | 7,448.00 |
| 2014-09-30 | 51,767.00 | 14,796.00 | 4,374.00 |
| 2014-06-30 | 51,767.00 | 14,796.00 | 4,374.00 |
| 2014-03-31 | 57,014.00 | 14,590.00 | 8,340.00 |
| 2013-12-31 | 57,033.00 | 14,590.00 | 8,340.00 |
| 2013-09-30 | 56,195.00 | 14,660.00 | 4,263.00 |
| 2013-06-30 | 56,195.00 | 14,660.00 | 4,263.00 |
| 2013-03-31 | 57,472.00 | 14,533.00 | 6,477.00 |
| 2012-12-31 | 57,486.00 | 14,533.00 | 6,477.00 |
| 2012-09-30 | 56,354.00 | 16,182.00 | 4,638.00 |
| 2012-06-30 | 56,354.00 | 16,182.00 | 4,638.00 |
- Sanofi's level of debt (41.7%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (25.6% vs 41.7% today).
- Debt is well covered by operating cash flow (22.5%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 15.4x coverage).
Financial health checks
We assess Sanofi's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Sanofi has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Sanofi's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Sanofi
shares you are expected to receive
€83
in your first year as a dividend.
Dividend Amount
- Sanofi's pays a higher dividend yield than the bottom 25% of dividend payers in France (1.57%).
- Sanofi's dividend is below the markets top 25% of dividend payers in France (4.28%).
Upcoming dividend payment
Purchase Sanofi before the 'Buy Limit' to receive their next dividend payment.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
| Europe Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 32 Stocks | 3.4% |
| France Market Average Dividend Yield | Market Cap Weighted Average of 324 Stocks | 2.9% |
| France Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| France Bottom 25% Dividend Yield | 25th Percentile | 1.6% |
| France Top 25% Dividend Yield | 75th Percentile | 4.3% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | 3.86 | 4.00 |
| 2022-12-31 | 3.78 | 4.00 |
| 2021-12-31 | 3.48 | 12.00 |
| 2020-12-31 | 3.34 | 18.00 |
| 2019-12-31 | 3.18 | 18.00 |
| Date (Data in €) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-03-08 | 3.070 | 3.970 |
| 2019-02-07 | 3.070 | 4.118 |
| 2018-05-02 | 3.030 | 4.143 |
| 2017-05-10 | 2.960 | 3.881 |
| 2016-05-04 | 2.930 | 3.909 |
| 2015-05-04 | 2.850 | 3.452 |
| 2014-04-29 | 2.800 | 3.441 |
| 2013-05-03 | 2.770 | 3.622 |
| 2012-03-06 | 2.650 | 4.032 |
| 2012-02-08 | 2.650 | 4.699 |
| 2011-02-09 | 2.500 | 4.841 |
| 2010-02-10 | 2.400 | 4.810 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Whilst dividend payments have been stable, Sanofi has been paying a dividend for less than 10 years.
- Dividend payments have increased, but Sanofi only paid a dividend in the past 9 years.
Income/ dividend checks
We assess Sanofi's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Sanofi afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Sanofi has a total score of 3/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | €7,276,022 |
| AGE | 62 |
| TENURE AS CEO | 4 years |
CEO Bio
Mr. Olivier Brandicourt, MD has been the Chief Executive Officer of Sanofi since April 2, 2015. Mr. Brandicourt serves as the Chief Executive Officer and President of Sanofi Pasteur Inc. Mr. Brandicourt served as Chief Executive Officer at Bayer HealthCare Pharmaceuticals Inc. since November 01, 2013. He served as the Chairman of the Management Board at Bayer HealthCare AG from November 1, 2013 to March 31, 2015 and also served as its Chief Executive Officer. Mr. Brandicourt served as the President and General Manager, the Emerging Markets and Established Products Business Units at Pfizer Inc. since June 1, 2012. He served as President of Pfizer Primary Care and General Manager of Pfizer Primary Care at Pfizer Inc. from 2009 to June 2012. Mr. Brandicourt served as the President and General Manager, Pfizer's worldwide primary care business at Pfizer Inc. from 2008 to June 1, 2012. He served as Senior Vice President and General Manager of U.S. Pratt Business Unit at Pfizer Inc. from 2007 to 2008. Mr. Brandicourt served as Managing Director of the United Kingdom/Ireland Pfizer subsidiary from 2004 to 2007. He has been a Director of Sanofi since April 2015. He served as Chairman of Bayer HealthCare Pharmaceuticals Inc. Mr. Brandicourt studied medicine, specialized in Infectious Diseases and Tropical Medicine from University of Paris V and holds an Advanced Degree in Cellular and Immunological Pathophysiology from the Paris Descartes University. He also holds a Master’s Degree in Biology from University of Paris XII.
CEO Compensation
- Olivier's compensation has been consistent with company performance over the past year.
- Olivier's remuneration is higher than average for companies of similar size in France.
Management Team Tenure
Average tenure and age of the Sanofi management team in years:
- The average tenure for the Sanofi management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Olivier Brandicourt
CEO & Director
€7M
62
4 yrs
Jean-Baptiste de Chatillon
Executive VP & CFO
53
0.5 yrs
Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Bruno Ménard
Chief Information officer
7.7 yrs
George Grofik
Head of Investor Relations
Karen Linehan
Executive VP of Legal Affairs & General Counsel
59
12.1 yrs
Dante Beccaria
Global Compliance Officer & VP
7 yrs
Pierre Chancel
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
61
14.7 yrs
Caroline Luscombe
Executive Vice President of Human Resources
58
0.5 yrs
Marie-Hélène Laimay
Senior Vice President of Audit & Internal Control Assessment
59
16.9 yrs
Board of Directors Tenure
Average tenure and age of the Sanofi board of directors in years:
- The tenure for the Sanofi board of directors is about average.
Board of Directors
Serge Weinberg
Chairman
€708K
67
8.9 yrs
Olivier Brandicourt
CEO & Director
€7M
62
4 yrs
Jean-François Dehecq
Honorary Chairman
€5M
78
8.9 yrs
Fabienne Lecorvaisier
Independent Director
€128K
56
5.9 yrs
Patrick Kron
Independent Director
€133K
65
4.9 yrs
Thomas Südhof
Independent Director
€120K
63
2.9 yrs
Claudie Haigneré
Independent Director
€108K
61
10.9 yrs
Carole Piwnica
Independent Director
€100K
60
8.3 yrs
Suet-Fern Lee
Independent Director
€118K
60
7.9 yrs
Laurent Attal
Director
€108K
60
6.9 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Sanofi's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Sanofi has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Is Sanofi's (EPA:SAN) Balance Sheet Strong Enough To Weather A Storm?
the key to their continued success lies in its financial health. … I will provide an overview of Sanofi’s financial liquidity and leverage to give you an idea of Sanofi’s position to take advantage of potential acquisitions or comfortably endure future downturns. … Note that this information is centred entirely on financial health and is a high-level overview, so I encourage you to look further
Simply Wall St - – Full articleWhat Should You Know About Sanofi's (EPA:SAN) Future?
The most recent earnings update Sanofi's (EPA:SAN) released in December 2018a … signalled … company
Simply Wall St - – Full articleRead This Before You Buy Sanofi (EPA:SAN) Because Of Its P/E Ratio
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Sanofi has a price to earnings ratio of 22.67, based on the last twelve months. … How Do I Calculate Sanofi's Price To Earnings Ratio
Simply Wall St - – Full articleIs Sanofi (EPA:SAN) Overpaying Its CEO?
This analysis aims first to contrast CEO compensation with other large companies. … How Does Olivier Brandicourt's Compensation Compare With Similar Sized Companies. … Our data indicates that Sanofi is worth €96b, and total annual CEO compensation is €7.3m.
Simply Wall St - – Full articleInvestors Who Bought Sanofi Shares A Year Ago Are Now Up 12%
To wit, the Sanofi (EPA:SAN) share price is 12% higher than it was a year ago, much better than the market return of around -0.6% (not including dividends) in the same period. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. … During the last year Sanofi grew its earnings per share (EPS) by 15%.
Simply Wall St - – Full articleShould You Be Concerned About Sanofi's (EPA:SAN) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every €1 worth of shareholders' equity, it generated €0.075 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleHave Investors Priced In Sanofi's (EPA:SAN) Growth?
Sanofi (EPA:SAN) is considered a high growth stock. … However its last closing price of €75.4 left investors wondering whether this growth has already been factored into the share price. … According to the analysts covering the company, the following few years should bring about good growth prospects for Sanofi
Simply Wall St - – Full articleSanofi (EPA:SAN): What Does The Future Look Like?
In September 2018, Sanofi (EPA:SAN) announced its earnings update. … the consensus outlook from analysts appear fairly confident, … as a 24% increase in profits is expected in the upcoming year,
Simply Wall St - – Full articleDo Directors Own Sanofi (EPA:SAN) Shares?
Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We'd expect to see both institutions and retail investors owning a portion of the company. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleShould You Be Concerned About Sanofi's (EPA:SAN) ROE?
Our data shows Sanofi has a return on equity of 6.0% for the last year. … One way to conceptualize this, is that for each €1 of shareholders' equity it has, the company made €0.060 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleCompany Info
Description
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia in adults and children; and Cablivi to treat acquired thrombotic thrombocytopenic purpura in adults. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, for hematologic malignancies; and Zaltrap, for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, a sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; consumer healthcare products for allergy, cough, cold, pain, nutrition, digestion, and others; and pediatric, influenza, adult and adolescent booster, meningitis, travel, and endemic vaccines. Sanofi was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Details
| Name: | Sanofi |
| SAN | |
| Exchange: | ENXTPA |
| Founded: | 1973 |
| €91,728,012,281 | |
| 1,245,965,937 | |
| Website: | http://www.sanofi.com |
| Address: |
Sanofi 54, Rue La Boétie, Paris, Ile-de-France, 75008, France |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTPA | SAN | Ordinary Shares | Euronext Paris | FR | EUR | 25. May 1999 | |
| OTCPK | SNYN.F | Ordinary Shares | Pink Sheets LLC | US | USD | 25. May 1999 | |
| DB | SNW | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 25. May 1999 | |
| XTRA | SNW | Ordinary Shares | XETRA Trading Platform | DE | EUR | 25. May 1999 | |
| LSE | 0O59 | Ordinary Shares | London Stock Exchange | GB | EUR | 25. May 1999 | |
| SWX | SAN | Ordinary Shares | SIX Swiss Exchange | CH | CHF | 25. May 1999 | |
| BIT | SANF | Ordinary Shares | Borsa Italiana | IT | EUR | 25. May 1999 | |
| WBAG | SANO | Ordinary Shares | Wiener Boerse AG | AT | EUR | 25. May 1999 | |
| BATS-CHIXE | SANP | Ordinary Shares | BATS 'Chi-X Europe' | GB | EUR | 25. May 1999 | |
| NasdaqGS | SNY | SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II | Nasdaq Global Select | US | USD | 01. Jul 2002 | |
| DB | SNW2 | SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II | Deutsche Boerse AG | DE | EUR | 01. Jul 2002 | |
| ENXTPA | SANNV | EUR2 (RFD 01/01/2019) | Euronext Paris | FR | EUR | 02. Jan 2019 | |
| BMV | SNY N | SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II | Bolsa Mexicana de Valores | MX | MXN | 01. Jul 2002 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/25 20:57 |
| End of day share price update: | 2019/04/25 00:00 |
| Last estimates confirmation: | 2019/04/17 |
| Last earnings filing: | 2019/03/08 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
